Sanofi agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as the French pharmaceuticals firm bets on next-generation mRNA vaccine technology beyond the Covid-19 pandemic, confirming a Reuters exclusive report.

Ipsen, a global biopharmaceutical firm that specializes in neuroscience, oncology and rare diseases, partnered with Exicure, a clinical-stage biotech company that develops treatments for neurological, inflammatory and genetic disorders, to create new therapies for Angelman syndrome (AS) and Huntington’s disease (HD).

Loxo Oncology, a division of Eli Lilly, and Kumquat Biosciences teamed up in a deal valued at more than $2 billion to discover and develop novel small molecules designed to stimulate tumor-specific immune responses in cancer patients.

Amgen is snapping up privately held Teneobio and the company’s class of biologics dubbed Human Heavy-Chain Antibodies in a deal that could total $2.5 billion.

Paris-based Ipsen inked a licensing deal with Sweden’s IRLAB for mesdopetam, a potential drug for Parkinson’s disease.

GlaxoSmithKline Plc and U.S. firm Alector Inc. will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on July 2.

Fingerpaint, a full-service health and wellness marketing firm with a global team of more than 580 people, acquired Splice, a healthcare communications business based in Emeryville, California.

Britain’s GlaxoSmithKline Plc agreed to pay up to $2 billion to iTeos Therapeutics Inc. to develop and sell a potential cancer treatment together, the companies said on June 14.

Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace took a look at some of these announcements.

British life sciences company NetScientific Plc said on June 7 that one of the company’s subsidiaries entered an exclusive licensing agreement with AstraZeneca Plc to globally sell a Covid-19 test.